Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Reactive astrocyte nomenclature, definitions, and future directions

(2021) Carole Escartin et al.   NATURE NEUROSCIENCE

A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis

(2021) MengJiao Sun et al.   Multiple Sclerosis and Related Disorders

Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis

(2021) Bruna Bellaver et al.   NEUROLOGY

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

(2021) Marta Milà-Alomà et al.   Alzheimers Research & Therapy

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage

(2020) Breton M. Asken et al.   JOURNAL OF ALZHEIMERS DISEASE

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

(2020) Alberto Benussi et al.   JOURNAL OF ALZHEIMERS DISEASE

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

(2019) Patrick Oeckl et al.   JOURNAL OF ALZHEIMERS DISEASE

Astrocyte Biomarkers in Alzheimer’s Disease

(2019) Stephen F. Carter et al.   TRENDS IN MOLECULAR MEDICINE

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

(2019) Ahmed Abdelhak et al.   Frontiers in Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's disease

(2019) Fanny M. Elahi et al.   Alzheimers & Dementia

CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia

(2019) Samir Abu-Rumeileh et al.   Alzheimers Research & Therapy

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

The pericyte–glia interface at the blood–brain barrier

(2018) Patrizia Giannoni et al.   CLINICAL SCIENCE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

(2018) Melanie D. Sweeney et al.   Nature Reviews Neurology

CSF Aβ1-42 Levels and Glucose Metabolism in Alzheimer's Disease>

(2018) Julien Dumurgier et al.   JOURNAL OF ALZHEIMERS DISEASE

In vivo quantification of neurofibrillary tangles with [18F]MK-6240

(2018) Tharick A. Pascoal et al.   Alzheimers Research & Therapy

Unknown

(2018)   ANNALS OF NEUROLOGY

Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease

(2017) Sarah Jesse et al.   JOURNAL OF ALZHEIMERS DISEASE

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury

(2016) Linda Papa et al.   JAMA Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study

(2015) Elena Rodriguez-Vieitez et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration

(2015) Aiko Ishiki et al.   JOURNAL OF NEUROCHEMISTRY

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

(2015) Daniel Alcolea et al.   NEUROLOGY

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography

(2015) Michael Schöll et al.   Scientific Reports

Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome

(2014) Ing-Marie Larsson et al.   RESUSCITATION

Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG

(2012) S. F. Carter et al.   JOURNAL OF NUCLEAR MEDICINE

A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid  

(2012) J. J. Iliff et al.   Science Translational Medicine

Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention

(2011) Linda Papa et al.   ANNALS OF EMERGENCY MEDICINE

Astrocytes in Alzheimer’s disease

(2010) Alexei Verkhratsky et al.   Neurotherapeutics

Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain

(2008) J.E. Simpson et al.   NEUROBIOLOGY OF AGING